A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
UCB Biopharma SRL
Study ID
NCT06921850
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
9 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

  • Bimekizumab — DRUG
    Bimekizumab will be administered at pre-specified timepoints.

Study Details

The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)

Key Dates

Start date
Apr 7, 2025
Status verified
Jun 2026
Primary completion
Dec 21, 2026
Completion
Mar 6, 2029

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bimekizumab
    Study participants will receive a bimekizumab dose which is weight-dependent.

Primary Outcome Measure

Geometric Mean Plasma bimekizumab concentrations at Week 16 [ Time Frame: At Week 16 ]

Central Contacts

Locations (12)

FacilityCityStateZIPSite coordinators
Hs0006 50175PhoenixArizona85006-
Hs0006 50708RosevilleCalifornia95661-
Hs0006 50684SacramentoCalifornia95815-
Hs0006 50707Washington D.C.District of Columbia20010-
Hs0006 50199MiamiFlorida33136-
Hs0006 50178ClarkstonMichigan48346-
Hs0006 50710Fort GratiotMichigan48059-
Hs0006 50711TroyMichigan48084-
Hs0006 50712New YorkNew York10023-
Hs0006 50706Chapel HillNorth Carolina27516-
Hs0006 50202FairbornOhio45324-
Hs0006 50201ArlingtonTexas76011-

Find similar trials in Phoenix, AZ

By condition
Hidradenitis suppurativa
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Hs0006 50175· Phoenix, AZHs0006 50708· Roseville, CAHs0006 50684· Sacramento, CAHs0006 50707· Washington D.C., DCHs0006 50199· Miami, FLHs0006 50178· Clarkston, MI

Related Studies